These data suggest that FHIT loss primarily activates the HRR repair pathway to mitigate genotoxic damage and that the HRR pathway, in addition to GSK3β, could be a druggable target for lung cancers with FHIT loss. The gene discussed is GSK3B; the disease is lung carcinoma.